The fact that GM-CSF is improving the diphtheria-, but not the tetanus-component of the multivalent vaccine is of interest, as there is no urgent need to boost protection against tetanus either in young or in elderly adults [3–5]. The gene discussed is CSF2; the disease is diphtheria.